Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract CT019: Biological mechanisms underlying objective responses in recurrent GBM patients treated with sequential bortezomib and temozolomide: An interim analysis of NCT03643549 Phase IB/II trial

Mohummad Aminur Rahman, Dorota Goplen, Andreas Waha, Leif Oltedal, Judit Haasz, Surendra Kumar, Even Birkeland, Hrvoje Miletic, Frode Selheim, Martha Chekenya

Cancer Res (2024) 84 (7_Supplement): CT019.

https://doi.org/10.1158/1538-7445.AM2024-CT019

Published: 05 April 2024

View article titled, Abstract CT019: Biological mechanisms underlying objective responses in recurrent GBM patients treated with sequential bortezomib and temozolomide: An interim analysis of NCT03643549 Phase IB/II trial

Journal Articles

Abstract 4494: Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma

Lasse Neset, Mia Kristin Nilsen, Victoria Smith Arnesen, Kazi Asraful Alam, Martha Chekenya, Mohummad Aminur Rahman

Cancer Res (2024) 84 (6_Supplement): 4494.

https://doi.org/10.1158/1538-7445.AM2024-4494

Published: 22 March 2024

View article titled, Abstract 4494: Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma

Journal Articles

Abstract 3996: A novel 13-basepair deletion in CSPG4/NG2 abrogates protein expression, glioblastoma proliferation and invasion in vitro and in vivo in mice

Victoria Smith Arnesen, Susina Suntharalingam, Żaneta Matuszek, Shahin Sarowar, Stian Knappskog, Stein Atle Lie, David R. Liu, Mohummad Aminur Rahman, Martha Chekenya

Cancer Res (2022) 82 (12_Supplement): 3996.

https://doi.org/10.1158/1538-7445.AM2022-3996

Published: 15 June 2022

View article titled, Abstract 3996: A novel 13-basepair deletion in CSPG4/NG2 abrogates protein expression, glioblastoma proliferation and invasion in vitro and in vivo in mice

Journal Articles

Abstract CT114: BORTEM-17 - phase IB/II single arm, non-randomized controlled multicenter study investigating whether sequential bortezomib and temozolomide is safe and effective in recurrent GBM with unmethylated MGMT promoter

Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke, Victoria Arnesen, Anne Simonsen, Andreas Waha, Kirstin Marienhagen, Leif Oltedal, Judit Haasz, Hrvoje Miletic, Tora Skeidsvoll Solheim, Petter Brandal, Stein Atle Lie, Martha Chekenya

Cancer Res (2022) 82 (12_Supplement): CT114.

https://doi.org/10.1158/1538-7445.AM2022-CT114

Published: 15 June 2022

View article titled, Abstract CT114: BORTEM-17 - phase IB/II single arm, non-randomized controlled multicenter study investigating whether sequential bortezomib and temozolomide is safe and effective in recurrent GBM with unmethylated MGMT promoter

Journal Articles

Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated MGMT promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux

Mohummad A. Rahman, Andrea G. Navarro, Jorunn Brekke, Christian Bindesbøll, Agnete Engelsen, Shahin Sarowar, Marzieh Bahador, Bjørn T. Gjertsen, Dorota Goplen, Per Ø. Enger, Frode Selheim, Anne Simonsen, Martha Chekenya

Cancer Res (2018) 78 (13_Supplement): 2928.

https://doi.org/10.1158/1538-7445.AM2018-2928

Published: 01 July 2018

View article titled, Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated <em>MGMT</em> promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux

Journal Articles

Abstract LB-195: Bortezomib sensitizes glioblastoma for NK cell immunotherapy

Andrea Gras Navarro, Aminur Rahman, Marzieh Bahador, Martha Chekenya Enger

Cancer Res (2017) 77 (13_Supplement): LB-195.

https://doi.org/10.1158/1538-7445.AM2017-LB-195

Published: 01 July 2017

View article titled, Abstract LB-195: Bortezomib sensitizes glioblastoma for NK cell immunotherapy

Journal Articles

Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients

Mev Dominguez–Valentin, Andrea Gras Navarro, Aminur Mohummad Rahman, Surendra Kumar, Christèle Retière, Elling Ulvestad, Vessela Kristensen, Morten Lund-Johansen, Benedicte Alexandra Lie, Per Øyvind Enger, Gro Njølstad, Einar Kristoffersen, Stein Atle Lie, Martha Chekenya

Cancer Res (2016) 76 (18): 5326–5336.

https://doi.org/10.1158/0008-5472.CAN-16-1162

Published: 15 September 2016

View article titled, Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients

Includes: Supplementary data

Journal Articles

Abstract 2807: Activated NK cells efficiently kill Glioblastoma through activating receptor-ligand interactions

Justyna Kmiecik, Andrea Gras Navarro, Per Øyvind Enger, Lina Leiss, Jacques Zimmer, Martha Chekenya

Cancer Res (2014) 74 (19_Supplement): 2807.

https://doi.org/10.1158/1538-7445.AM2014-2807

Published: 01 October 2014

View article titled, Abstract 2807: Activated NK cells efficiently kill Glioblastoma through activating receptor-ligand interactions

Journal Articles

Abstract LB-332: Purified ex vivo expanded and activated human Natural Killer cells efficiently kill glioblastoma cells in a dose- and donor-dependent manner.

Justyna Kmiecik, Andrea Gras Navarro, Per Ø. Enger, Mateusz Zelkowski, Jacques Zimmer, Martha Chekenya Enger

Cancer Res (2013) 73 (8_Supplement): LB-332.

https://doi.org/10.1158/1538-7445.AM2013-LB-332

Published: 15 April 2013

View article titled, Abstract LB-332: Purified <em>ex vivo</em> expanded and activated human Natural Killer cells efficiently kill glioblastoma cells in a dose- and donor-dependent manner.

Journal Articles

Abstract 3542: Interplay between cancer and the immune system: Beneficial role of TILs and mechanisms of tumor immune escape in GBM patients

Justyna Kmiecik, Aurélie Poli, Nicolaas H. C. Brons, Jacques Zimmer, Martha Chekenya

Cancer Res (2012) 72 (8_Supplement): 3542.

https://doi.org/10.1158/1538-7445.AM2012-3542

Published: 15 April 2012

View article titled, Abstract 3542: Interplay between cancer and the immune system: Beneficial role of TILs and mechanisms of tumor immune escape in GBM patients

Journal Articles

Abstract 3509: Intracranial administration of activated NK-cells and mAb9.2.27 against NG2/CSPG4 activates microglial cytotoxicity and prolongs survival in glioblastoma xenograft model

Aurelie Poli, Jian Wang, Olivia Domingues, Tao Yan, Frits Thorsen, Cecilie Brekke-Rygg, Francois Hentges, Paal Henning Pedersen, Jacques Zimmer, Per Øyvind Enger, Martha Chekenya

Cancer Res (2012) 72 (8_Supplement): 3509.

https://doi.org/10.1158/1538-7445.AM2012-3509

Published: 15 April 2012

View article titled, Abstract 3509: Intracranial administration of activated NK-cells and mAb9.2.27 against NG2/CSPG4 activates microglial cytotoxicity and prolongs survival in glioblastoma xenograft model

Journal Articles

Abstract 528: A tumor-stroma interaction study in red mammary tumors in green mice with and without enhanced oxygenation

Ingrid Moen, Charlotte Jevne, Jian Wang, Karl-Henning Kalland, Martha Chekenya, Lars A. Akslen, Linda Sleire, Per Øyvind Enger, Rolf K. Reed, Anne M. Øyan, Linda E.B. Stuhr

Cancer Res (2011) 71 (8_Supplement): 528.

https://doi.org/10.1158/1538-7445.AM2011-528

Published: 15 April 2011

View article titled, Abstract 528: A tumor-stroma interaction study in red mammary tumors in green mice with and without enhanced oxygenation

Journal Articles

Abstract #LB-64: Modulation of experimental gliomas: Phenotypic progression from gliomatosis cerebri-like lesions to glioblastoma.

Jian Wang, Hrvoje Miletic, Per Øystein Sakariassen, Peter Huszthy, Hege Jacobsen, Xingang Li, Martha Chekenya, Rolf Bjerkvig, Per Øyvind Enger

Cancer Res (2009) 69 (9_Supplement): LB-64.

Published: 01 May 2009

View article titled, Abstract #LB-64: Modulation of experimental gliomas: Phenotypic progression from gliomatosis cerebri-like lesions to glioblastoma.

Journal Articles

Abstract #4186: Phenotypic and functional characteristics of rat natural killer cells purified by negative versus positive selection show differential anti-tumor effects: implications for anti-tumor therapy

Aurélie Poli, François Hentges, Jacques Zimmer, Martha Chekenya

Cancer Res (2009) 69 (9_Supplement): 4186.

Published: 01 May 2009

View article titled, Abstract #4186: Phenotypic and functional characteristics of rat natural killer cells purified by negative versus positive selection show differential anti-tumor effects: implications for anti-tumor therapy

Journal Articles

The progenitor cell marker NG2/MPG promotes chemoresistance byactivation of integrin-dependent PI3K/Akt signaling

Martha chekenya, Agnete Svendsen, Inger Netland, Vidar Staalesen, Berit Tysnes, Frode Selheim, Jian Wang, Per Lonning, Per Enger, Rolf Bjerkvig, Mouldy Siuod, William Stallcup

Cancer Res (2008) 68 (9_Supplement): LB-273.

Published: 01 May 2008

View article titled, The progenitor cell marker NG2/MPG promotes chemoresistance byactivation of integrin-dependent PI3K/Akt signaling

Journal Articles

NG2/HMP promotes radioresistance by elevated peroxiredoxin-1 resulting in rapid activation of the DNA damage response in GBM

Inger Anne Netland, Joost Verhoeff, Anneli Kjersem, Agnete Svendsen, Jan Brogger, Jesus Planagoma, Per Oystein Sakariassen, Gro Rosland, Morten Lund-Johansen, Rolf Bjerkvig, Per Oyvind Enger, Martha Chekenya

Cancer Res (2008) 68 (9_Supplement): LB-312.

Published: 01 May 2008

View article titled, NG2/HMP promotes radioresistance by elevated peroxiredoxin-1 resulting in rapid activation of the DNA damage response in GBM

NARROW

Abstract CT019: Biological mechanisms underlying objective responses in recurrent GBM patients treated with sequential bortezomib and temozolomide: An interim analysis of NCT03643549 Phase IB/II trial

Abstract 4494: Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma

Abstract 3996: A novel 13-basepair deletion in CSPG4/NG2 abrogates protein expression, glioblastoma proliferation and invasion in vitro and in vivo in mice

Abstract CT114: BORTEM-17 - phase IB/II single arm, non-randomized controlled multicenter study investigating whether sequential bortezomib and temozolomide is safe and effective in recurrent GBM with unmethylated MGMT promoter

Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylated MGMT promoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux

Abstract LB-195: Bortezomib sensitizes glioblastoma for NK cell immunotherapy

Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients

Abstract 2807: Activated NK cells efficiently kill Glioblastoma through activating receptor-ligand interactions

Abstract LB-332: Purified ex vivo expanded and activated human Natural Killer cells efficiently kill glioblastoma cells in a dose- and donor-dependent manner.

Abstract 3542: Interplay between cancer and the immune system: Beneficial role of TILs and mechanisms of tumor immune escape in GBM patients

Abstract 3509: Intracranial administration of activated NK-cells and mAb9.2.27 against NG2/CSPG4 activates microglial cytotoxicity and prolongs survival in glioblastoma xenograft model

Abstract 528: A tumor-stroma interaction study in red mammary tumors in green mice with and without enhanced oxygenation

Abstract #LB-64: Modulation of experimental gliomas: Phenotypic progression from gliomatosis cerebri-like lesions to glioblastoma.

Abstract #4186: Phenotypic and functional characteristics of rat natural killer cells purified by negative versus positive selection show differential anti-tumor effects: implications for anti-tumor therapy

The progenitor cell marker NG2/MPG promotes chemoresistance byactivation of integrin-dependent PI3K/Akt signaling

NG2/HMP promotes radioresistance by elevated peroxiredoxin-1 resulting in rapid activation of the DNA damage response in GBM

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only